Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Item
http://www.wikidata.org/entity/Q42510173
Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancerNottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?Alterations in cell cycle and induction of apoptotic cell death in breast cancer cells treated with α-mangostin extracted from mangosteen pericarpNEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancerThe epidemiology of triple-negative breast cancer, including racePhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerLoss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancersUnderstanding and treating triple-negative breast cancerRisk factors for triple-negative breast cancer in women under the age of 45 yearsTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Advances in mass spectrometry-based clinical biomarker discoveryManaging breast cancer in younger women: challenges and solutionsMiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerBiomarkers in triple negative breast cancer: A reviewTargeted Therapies in Triple-Negative Breast CancerClinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature reviewEverolimus in the Treatment of Metastatic Breast CancerTargeting triple-negative breast cancer: optimising therapeutic outcomesEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestryAn unsupervised MVA method to compare specific regions in human breast tumor tissue samples using ToF-SIMSEstrogen-Related Receptors in Breast Cancer and Prostate CancerNovel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cellsPanepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancerNovel genes associated with lymph node metastasis in triple negative breast cancerBreast cancer subtypes and previously established genetic risk factors: a bayesian approachSrc Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun PathwayEvolutionary foundations for cancer biologyBreast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian populationAntitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancersGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision.Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.Triple receptor-negative breast cancer: imaging and clinical characteristics.Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers.Yellow fever vaccine 17D administered to healthy women aged between 40 and 54 years halves breast cancer risk: an observational study.Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target TherapyAssociation of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011).Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.
P2860
Q21134780-C68FDD60-3A86-460E-B036-FDE4D714C859Q21261291-57D7CD04-4261-483C-AFDF-7DB3BC8CE9C7Q21285004-E1F23B1A-50B8-487A-A571-4DCA3E015047Q21560948-9D08D66C-9034-4230-8A46-37B07C2EFDF5Q24289471-E36AD850-38F1-4E6A-B370-95B302C6D32EQ24563045-901602D7-13BA-411A-AFC6-C879DADA2D3BQ24620397-AD3C7FF4-627B-42C4-9047-7F775BDF74BEQ24620957-8640E185-640C-4EA9-A110-DD768E8A2BC3Q24644075-792EF005-241B-4793-9562-4EF20A6875BDQ26745420-E29E6073-DB5A-425A-AFA3-808CCCE810D4Q26770004-745B020B-AAD5-4232-B146-4ED1BD5BA748Q26771184-5BD76CFF-287E-4C23-A874-385AF806CE88Q26775086-F15C1810-E467-48D8-A154-BEAAFF15E695Q26775094-E8AAFF14-3950-4B92-A675-E45A9490BF97Q26777736-E8B27EDD-B356-4E02-B8A3-993854ADE303Q26783596-6372710F-7189-4676-90A8-2C6FE1FAB6BEQ26784920-6A7CA523-5DE8-4953-9222-E19F316C0E63Q26850892-62990BB3-BA44-4404-8CF1-A99DC658EA5DQ27011535-94887007-1264-401D-A5B3-6C75548EB537Q27334982-57E261BF-7183-4EA6-BE41-28A0C442A175Q28084030-3A0B6953-B5F4-4E88-85AD-A050416A2031Q28259152-4D544C9E-33CC-4650-92BB-0F1655144BF8Q28387216-543A0918-B66B-40A6-9D74-E9CCF5A81083Q28393204-07EC5DB8-5187-4409-A244-10D6F422C5B3Q28397311-A1C41709-E7D8-4B41-BDFC-C5E16E44BE7EQ28468471-C7AFB178-AE4F-452D-B7EC-FDF58443C425Q28709090-40782486-4DA7-4760-ADF3-A02BE0CE6FCEQ29006708-403E81DB-C33B-4458-AD0D-F08B7B4F11AEQ29248485-DE4D96E3-80D0-4C27-A210-671BF011007FQ29417100-4CE1107F-684F-443D-968D-F0BB88371803Q30409456-B29749E8-A2E2-438D-906A-895C93B7B144Q30437453-1DCA0452-8F7B-47B4-84AA-41C52DF9BE51Q30455153-411D46E9-96AB-49D5-BDA6-D2D4252D8B2FQ30474511-215867A6-8C99-434B-AEF6-E4EFEAF4F5D3Q30490366-34FD360D-A071-4A83-B39F-04D96422056EQ30541773-6555B366-B39F-4D4B-ABE1-5603C99D98B2Q30663777-96E90B88-AB4F-47D5-8717-89FFC460679CQ30813968-3557C623-C5FE-47C8-8E4C-26622E4D09BEQ30823443-D6C4AA57-EDF0-4CE4-A8D4-D01162D0314FQ30870747-4C4B38F3-43BA-4455-B829-593B5453FA4E
P2860

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Item
http://www.wikidata.org/entity/Q42510173
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Descriptive analysis of estrog ...... he California cancer Registry.
@en
Descriptive analysis of estrog ...... he California cancer Registry.
@nl
type
label
Descriptive analysis of estrog ...... he California cancer Registry.
@en
Descriptive analysis of estrog ...... he California cancer Registry.
@nl
prefLabel
Descriptive analysis of estrog ...... he California cancer Registry.
@en
Descriptive analysis of estrog ...... he California cancer Registry.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Descriptive analysis of estrog ...... he California cancer Registry.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921